SPOTLIGHT -
Rationale for Evaluating Ceritinib in ALK-Positive Patients With NSCLC
Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.